nafamostat has been researched along with Innate Inflammatory Response in 11 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nafamostat has been shown to have other, immunomodulatory effects, which may be beneficial for treatment, however animal models of ssRNA virus infection are lacking." | 5.72 | Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness. ( Anthony, DC; Dunstan, IK; Strekalova, T; Weglinski, CM; Yates, AG; Ying, Y, 2022) |
| "Nafamostat mesilate treatment significantly improved locomotion recovery as assessed by hindlimb BBB scores and the inclined plane test." | 5.48 | Nafamostat mesilate attenuates inflammation and apoptosis and promotes locomotor recovery after spinal cord injury. ( Duan, HQ; Fan, BY; Feng, SQ; Kong, XH; Li, B; Shi, HY; Sun, C; Wu, QL; Yao, X; Zhang, Y; Zhao, CX; Zhou, XF, 2018) |
| "After transient middle cerebral artery occlusion (tMCAO) in rats, NM reduced the infarct size, improved behavioral functions, decreased the expression of proinflammatory mediators (TNF-α, IL-1β, iNOS and COX-2) in a time-dependent manner and promoted the expression of different anti-inflammatory factors (CD206, TGF-β, IL-10 and IL-4) at different time points." | 5.43 | Nafamostat mesilate improves function recovery after stroke by inhibiting neuroinflammation in rats. ( Chen, T; Fang, Y; Li, C; Liao, H; Liu, Y; Sun, H; Wang, J; Zhou, XF, 2016) |
| "Nafamostat mesilate (NM), a synthetic broad-spectrum serine protease inhibitor, has been commonly used for treating acute pancreatitis (AP) and other inflammatory-associated diseases in some East Asia countries." | 4.31 | Nafamostat mesilate prevented caerulein-induced pancreatic injury by targeting HDAC6-mediated NLRP3 inflammasome activation. ( Chen, P; He, WQ; Huang, L; Liu, Y; Ren, JD; Tang, YR; Zhao, LJ, 2023) |
| " However, the effects of the serine protease inhibitors nafamostat mesilate (FUT), gabexate mesilate (FOY), and ulinastatin (UTI) on a long-term challenged mouse model of chronic asthma are unclear." | 3.80 | The effect of serine protease inhibitors on airway inflammation in a chronic allergen-induced asthma mouse model. ( Chao, YP; Chiang, CJ; Kao, ST; Lin, CC; Lin, J; Lin, LJ; Wang, SD, 2014) |
| "Nafamostat has been shown to have other, immunomodulatory effects, which may be beneficial for treatment, however animal models of ssRNA virus infection are lacking." | 1.72 | Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness. ( Anthony, DC; Dunstan, IK; Strekalova, T; Weglinski, CM; Yates, AG; Ying, Y, 2022) |
| "Nafamostat mesilate treatment significantly improved locomotion recovery as assessed by hindlimb BBB scores and the inclined plane test." | 1.48 | Nafamostat mesilate attenuates inflammation and apoptosis and promotes locomotor recovery after spinal cord injury. ( Duan, HQ; Fan, BY; Feng, SQ; Kong, XH; Li, B; Shi, HY; Sun, C; Wu, QL; Yao, X; Zhang, Y; Zhao, CX; Zhou, XF, 2018) |
| "After transient middle cerebral artery occlusion (tMCAO) in rats, NM reduced the infarct size, improved behavioral functions, decreased the expression of proinflammatory mediators (TNF-α, IL-1β, iNOS and COX-2) in a time-dependent manner and promoted the expression of different anti-inflammatory factors (CD206, TGF-β, IL-10 and IL-4) at different time points." | 1.43 | Nafamostat mesilate improves function recovery after stroke by inhibiting neuroinflammation in rats. ( Chen, T; Fang, Y; Li, C; Liao, H; Liu, Y; Sun, H; Wang, J; Zhou, XF, 2016) |
| ", Forssman shock, Forssman cutaneous vasculitis, zymosan-induced paw edema, endotoxin shock and local Shwartzman reaction, FUT-175 was highly effective in that, for example, intravenous dosing at 3 mg/kg could completely protect guinea pigs from the lethal Forssman shock." | 1.27 | Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. ( Aoyama, T; Fujita, M; Ino, Y; Koshiyama, Y; Oda, M; Ozeki, M; Sato, T; Suzuki, S, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Yates, AG | 1 |
| Weglinski, CM | 1 |
| Ying, Y | 1 |
| Dunstan, IK | 1 |
| Strekalova, T | 1 |
| Anthony, DC | 1 |
| Chen, P | 1 |
| Zhao, LJ | 1 |
| Huang, L | 1 |
| He, WQ | 1 |
| Tang, YR | 1 |
| Liu, Y | 2 |
| Ren, JD | 1 |
| Duan, HQ | 1 |
| Wu, QL | 1 |
| Yao, X | 1 |
| Fan, BY | 1 |
| Shi, HY | 1 |
| Zhao, CX | 1 |
| Zhang, Y | 1 |
| Li, B | 1 |
| Sun, C | 1 |
| Kong, XH | 1 |
| Zhou, XF | 2 |
| Feng, SQ | 1 |
| Lin, CC | 1 |
| Lin, LJ | 1 |
| Wang, SD | 1 |
| Chiang, CJ | 1 |
| Chao, YP | 1 |
| Lin, J | 1 |
| Kao, ST | 1 |
| Li, C | 1 |
| Wang, J | 1 |
| Fang, Y | 1 |
| Chen, T | 1 |
| Sun, H | 1 |
| Liao, H | 1 |
| Hu, HC | 1 |
| Wang, TY | 1 |
| Chen, YC | 1 |
| Wang, CC | 1 |
| Lin, MC | 1 |
| Ishimaru, K | 1 |
| Mitsuoka, H | 1 |
| Unno, N | 1 |
| Inuzuka, K | 1 |
| Nakamura, S | 1 |
| Schmid-Schönbein, GW | 1 |
| Aoyama, T | 1 |
| Ino, Y | 1 |
| Ozeki, M | 1 |
| Oda, M | 1 |
| Sato, T | 1 |
| Koshiyama, Y | 1 |
| Suzuki, S | 1 |
| Fujita, M | 1 |
| Kirschfink, M | 1 |
| Yanamoto, H | 1 |
| Kikuchi, H | 1 |
| Okamoto, S | 1 |
| Nozaki, K | 1 |
| Issekutz, AC | 1 |
| Roland, DM | 1 |
| Patrick, RA | 1 |
1 review available for nafamostat and Innate Inflammatory Response
| Article | Year |
|---|---|
Targeting complement in therapy.
Topics: Anaphylatoxins; Angioedema; Animals; Animals, Genetically Modified; Anti-Inflammatory Agents; Antibo | 2001 |
10 other studies available for nafamostat and Innate Inflammatory Response
| Article | Year |
|---|---|
Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness.
Topics: Animals; Benzamidines; COVID-19; COVID-19 Drug Treatment; Guanidines; Illness Behavior; Imidazoles; | 2022 |
Nafamostat mesilate prevented caerulein-induced pancreatic injury by targeting HDAC6-mediated NLRP3 inflammasome activation.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Ceruletide; Histone Deacetylase 6; Inflammasomes; | 2023 |
Nafamostat mesilate attenuates inflammation and apoptosis and promotes locomotor recovery after spinal cord injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Benzamidines; Disease Models, Animal; F | 2018 |
The effect of serine protease inhibitors on airway inflammation in a chronic allergen-induced asthma mouse model.
Topics: Allergens; Animals; Asthma; Benzamidines; Disease Models, Animal; Gabexate; Glycoproteins; Guanidine | 2014 |
Nafamostat mesilate improves function recovery after stroke by inhibiting neuroinflammation in rats.
Topics: Animals; Behavior, Animal; Benzamidines; Disease Models, Animal; Guanidines; Infarction, Middle Cere | 2016 |
RNA interference inhibits high mobility group box 1 by lipopolysaccharide-activated murine macrophage RAW 264.7 secretion.
Topics: Animals; Benzamidines; Cell Line; Cytokines; Down-Regulation; Guanidines; HMGB1 Protein; Inflammatio | 2011 |
Pancreatic proteases and inflammatory mediators in peritoneal fluid during splanchnic arterial occlusion and reperfusion.
Topics: Animals; Arteries; Benzamidines; Blood Pressure; Cardiovascular System; Endopeptidases; Enzyme Inhib | 2004 |
Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments.
Topics: Animals; Anti-Inflammatory Agents; Benzamidines; Complement Activation; Complement Inactivator Prote | 1984 |
Preventive effect of synthetic serine protease inhibitor, FUT-175, on cerebral vasospasm in rabbits.
Topics: Animals; Benzamidines; Cerebral Angiography; Cerebral Arteries; Complement Activation; Drug Evaluati | 1992 |
The effect of FUT-175 (Nafamstat Mesilate) on C3a, C4a and C5a generation in vitro and inflammatory reactions in vivo.
Topics: Animals; Benzamidines; Complement C3a; Complement C4a; Complement C5a; Complement Inactivator Protei | 1990 |